BioCentury
ARTICLE | Clinical News

CMX-2043: Phase IIa started

July 14, 2014 7:00 AM UTC

Ischemix began the double-blind, placebo-controlled Phase IIa CARIN trial to evaluate single doses of 2.4 and 3.6 mg/kg IV CMX-2043 and 2 doses of 2.4 mg/kg IVCMX-2043 given 24 hours apart in about 24...